Two mitochondrial peptides, two completely different playbooks. One signals, the other shields.
Bottom line: MOTS-c talks to your cells about metabolism. SS-31 physically shields your mitochondrial membranes from damage. MOTS-c is the metabolic optimizer, SS-31 is the structural protector. If exercise and metabolic performance matter most, lean MOTS-c. If organ protection and anti-aging at the cellular level is the goal, SS-31 has more clinical runway. Both are very early-stage for human use.
| MOTS-c | SS-31 | |
|---|---|---|
| Category | Mitochondrial-derived peptide (metabolic signaling) | Synthetic tetrapeptide (mitochondrial membrane protectant) |
| Mechanism | Encoded by mitochondrial DNA — activates AMPK, migrates to nucleus under stress to regulate gene expression for inflammation and repair | Penetrates inner mitochondrial membrane, stabilizes cardiolipin, protects electron transport chain from oxidative damage |
| Reported dose | 5–10 mg subcutaneous, 2–3x weekly | 1–5 mg subcutaneous, daily |
| Frequency | 2–3x per week, or every 5 days for 4 injections (20-day cycle) | Daily injection, typical 8–12 week protocol |
| Weight loss (trials) | Indirect — improved glucose tolerance (35% in aged mice) and exercise capacity (42% increase) | Not a weight loss peptide — targets mitochondrial function |
| Top side effect | Limited data — mild injection site reactions reported | Limited data — injection site reactions, potential mild GI effects |
| Evidence tier | Tier 3 — animal data strong, one Phase 2 human trial underway | Tier 2–3 — human trials for heart failure and kidney disease (as elamipretide), some Phase 2/3 data |
| Common vial size | 10 mg vials | 5 mg or 10 mg vials |
| Approval status | Not FDA-approved. Moved to Category 1 (Feb 2026) | Not FDA-approved. Elamipretide (branded form) has orphan drug designation for Barth syndrome |
MOTS-c is the choice when metabolic health is the target — insulin sensitivity, exercise performance, aging-related metabolic decline. It is a signaling molecule that tells your cells to adapt. Think metabolic resilience and energy production.
SS-31 is for mitochondrial structural protection — when the goal is preventing or reversing oxidative damage to mitochondria. Stronger data for heart and kidney applications. Think damage prevention rather than metabolic signaling.
MOTS-c talks to your cells about metabolism. SS-31 physically shields your mitochondrial membranes from damage. MOTS-c is the metabolic optimizer, SS-31 is the structural protector. If exercise and metabolic performance matter most, lean MOTS-c. If organ protection and anti-aging at the cellular level is the goal, SS-31 has more clinical runway. Both are very early-stage for human use.
← Browse all peptides | All comparisons →
vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify